Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 184.82

-2.0%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Bogdanoff who wrote (14847)	2/12/1998 3:10:00 PM
From: Andrew H	Read Replies (1) of 32384

>> I was responding to a post which suggested that phase 1 trials in one target population (diabetes in this case) proved or could prove safety in another target population(i.e. breast cancer). My statement was nothing more, or less, than that and I stand by it<< David, if you will read my post carefully, you will see that was not what it suggested--had you read the other recent posts in this context, you would have understood that. However, come to think of it, Targretin went directly into P2 diabetes without having to do a P1, although it had been shown to be safe only in cancer patients. This seems to contradict your statement.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next